Discover & Learn

Discover how our end-to-end radiopharmacy solutions can support your production goals.

Our team is ready to discuss cyclotron and radiochemistry technologies, as well as comprehensive integrated solutions for efficient and reliable radiopharmaceutical production.

Take the chance to exchange on current projects, technical challenges, and future plans.

For decades, medicine looked at the anatomy of the human body, observed at a single moment in time. Traditional imaging techniques, like X-rays, captured static images, revealing shapes and structures. It showed visible abnormalities but did not explain the underlying causes.
 

Nuclear medicine is something different than common medicine. You cannot touch it. Instead of looking at anatomy, nuclear medicine follows the clues inside the body, tracking biological processes. This molecular pursuit provides real-time insights into the behavior of organs, tissues, and cells.

Prof Dr Renata Mikolajczak, PhD - Research and Cooperation Manager, Radioisotope Center POLATOM National Center for Nuclear Research, Poland.

With over 30 years in radioisotope and radiopharmaceutical development, Prof Dr Renata Mikolajczak is coordinating the research activity of the Radioisotope Centre POLATOM, National Centre for Nuclear Research in Poland.

She is a Professor of medical sciences and holds a Ph.D. in physics and a DSc in medical biology.

Since 2020, she has served as the chair of the expert group, PRP Working Party - Precursors for Radiopharmaceutical Preparations,  European Pharmacopoeia of EDQM

She is a IAEA expert and lecturer in Radiopharmacy and member of the IAEA’s Standing Advisory Group on Nuclear Applications (SAGNA).

Everyone in the industry has seen the $12–14 billion projection for 2030. This white paper addresses the main question: what would actually have to change across the full chain for that number to become real? 
 

Jean-Michel Geets, Principal Domain Expert & IBA Fellow
Louise Piron, Marketing Manager

This webinar explored the Targeted Alpha Therapy (TAT) workflow, from accelerator-driven production to early clinical use, featuring renowned speakers, Prof Dr Tadashi Watabe from Osaka University, Mrs Clémence Maingueneau, PhD, from Arronax Nantes, and Mr Jean-Michel Geets, IBA Fellow and Domain Principal Expert; and moderated by Mrs Cristiana Gameiro, PhD, IBA Fellow and Domain Expert in radiochemistry.

IBA today launches Cyclone^® iKure, a dedicated cyclotron for routine Astatine-211 (²¹¹At) production. Designed for alpha-beam irradiation, this new cyclotron enables radiopharmaceutical manufacturers, research institutions and healthcare providers to accelerate access to targeted alpha therapies with the reliability and quality required for clinical-scale programs.